Blood cancer antibody testing study
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new way to check how blood cancers respond to immunotherapy. It looks at small blood or bone marrow samples before and during treatment to help doctors choose the best therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a blood cancer (like leukemia, lymphoma, or myeloma)
- Your doctor thinks immunotherapy may help you
- You haven't had chemotherapy for at least 4 weeks before joining
- You are covered by French health insurance
- You can read and understand French well enough to agree to take part
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows adults who are being checked for a possible blood cancer, or who were recently diagnosed with a blood cancer within the last 6 months. It may help doctors understand the condition better and improve how early workups and care are organized.
This trial studies a blood test that looks for circulating tumor markers in people with any type of invasive cancer (newly diagnosed or suspected). The goal is to see if markers in the blood can help monitor the cancer and guide treatment.
This study looks at immune system “fingerprints” in people who are planning to receive CAR-T cells. It may help doctors understand how the immune system responds to CAR-T and improve future care.
This study collects extra blood samples during your routine care to look for markers that might help predict how well cancer treatments work and how long people live. Participating involves no extra procedures beyond what you already need.
This study uses a simple blood test to look at the genetic makeup of your tumor. The results may help your doctors choose the best treatment for you. You will need to provide a tumor sample or have a biopsy.
This trial looks at blood samples to measure substances that may reflect cancer (tumor markers). It may help doctors understand cancer better and improve future monitoring, as long as you can safely and regularly take part.
Hear when a new Hematological Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.